Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIQ - Post by User

IMV Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by antisenseon Feb 08, 2023 11:18am
443 Views
Post# 35274481

Presenting on Friday 10th at 2 pm

Presenting on Friday 10th at 2 pmIMV is presenting their data on Friday Feb 10 at 2 pm at the conference:

  • 2:00 pm

  • Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate Sustained Anti-cancer Immunity and Durable Clinical Benefit

    This talk addresses:

    • The unique capability of the DPX vaccine platform to package diverse immune cargo (Neo- and tumor-associated antigens, immune modulators) into a single formulation for delivery to APCs and flow through lymph nodes.
    • The phase 2 clinical experience with the lead DPX asset, Maveropepimut-S (MVP-S), shows clear evidence of sustained immune response and deep, durable clinical benefit.
    • Updates on patient responses including complete responses in relapsed/ refractory DLBCL, advanced ovarian cancers and metastatic bladder cancers.


    Jeremy Graff, PhD
    CSO, IMV Inc

    https://theconferenceforum.org/conferences/immuno-oncology-360/2023-agenda/#day-93648-tab

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities